Biomarkers, type II collagen, glucosamine and chondroitin sulfate in osteoarthritis follow-up: The Magenta osteoarthritis study""

被引：55

作者：

Scarpellini M. ^{[1
]}

Lurati A. ^{[1
]}

Vignati G. ^{[2
]}

Marrazza M.G. ^{[1
]}

Telese F. ^{[1
]}

Re K. ^{[1
]}

Bellistri A. ^{[1
]}

机构：

[1] Rheumatology Unit, Magenta Hospital Italy, 20013 Magenta, Milan

[2] Endocrine and Metabolic Disease Center, Magenta Hospital Italy, 20013 Magenta, Milan

来源：

Journal of Orthopaedics and Traumatology | 2008年 / 9卷 / 2期

关键词：

Cartilage; Osteoarthritis; Type II collagen; uCTX-I; uCTX-II;

D O I：

10.1007/s10195-008-0007-5

中图分类号：

学科分类号：

摘要：

Background: The purpose of the present study was to determine relationship between disease activity, systemic markers of cartilage degradation, urinary C-terminal cross-linking telopeptides of type II collagen (uCTX-II), and bone degradation, urinary C-terminal cross-linking telopeptides of type I collagen (uCTX-I), structural progression of osteoarthritis (OA) and potential therapeutic efficacy of type II collagen (COLLII) in combination with glucosamine and chondroitin sulfate (GC). Materials and methods: An observational retrospective study, 1-year follow-up, on 104 patients with OA (nodular osteoarthritis of the hand, erosive osteoarthritis of the hand, EOA, osteoarthritis of the knee or hip) who were treated with GC or glucosamine, chondroitin sulfate and collagen type II (GCC). The following information was collected at entry: demographics, BMI, characteristics of OA, patient global assessment (VAS), C-terminal cross-linking telopeptides of collagen types I (uCTX-I) and II (uCTX-II) and radiographs. After 6 months: VAS, uCTX-I and uCTX-II. After 1 year: VAS, uCTX-I, uCTX-II and radiographs. Results: After 6 months and 1 year of treatment VAS, uCTX-I and uCTX-IImean values were significantly lower than the baseline. 57 were treated with GCC and 47 with GC. The group that received GCC showed a similar VAS mean value after 6 months and 1 year when compared with the group treated with GC. uCTX-I and uCTX-II mean level was lower in the group treated with GCC (P < 0.05). Radiological score (Kellgren and Lawrence summarized score for hands) after 1 year showed a reduced progression compared to the baseline in the hand osteoarthritis group, especially after GCC treatment (P < 0.05). Finally, uCTX-I has better correlation with radiological score and with GC in the EOA subgroup (Pearson index: R = 0.44). Conclusions: (a) uCTX-I and uCTX-II proved to be useful biomarkers in OA monitoring; (b) uCTX-I is better correlated with hand EOA and could represent a potential further marker to assess the evolution of EOA bone damage; (c) GC slow down OA progression; (d) finally COLLII could represent a further protective factor in OA cartilage. © Springer-Verlag 2008.

引用

页码：81 / 87

页数：6

共 29 条

[1]

Ihyc A., Osiecka-Iwan A., Jozwiak J., Moskalewski S., The morphology and selected biological properties of articular cartilage, Ortop Traumatol Rehabil, 3, 2, pp. 151-162, (2001)

[2]

Morales T.I., Chondrocyte moves: Clever strategies?, Osteoarthritis Cartilage, 15, 8, pp. 861-871, (2007)

[3]

Reijman M., Hazes J.M., Bierma-Zeinstra S.M., Koes B.W., Christgau F., Christiansen C., Uitterlinden A.G., Pols H.A., A new marker for osteoarthritis: Cross-sectional and longitudinal approach, Arthritis Rheum, 50, 8, pp. 2471-2478, (2004)

[4]

Charni N., Juillet F., Garnero P., Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis, Arthritis Rheum, 52, 4, pp. 1081-1090, (2005)

[5]

Jordan K.M., Syddall H.E., Garnero P., Gneyts E., Dennison E.M., Sayer A.A., Delmas P.D., Cooper C., Arden N.K., Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men, Ann Rheum Dis, 65, 7, pp. 871-877, (2006)

[6]

Bruyere O., Collette J., Kothari M., Zaim S., White D., Genant H., Peterfy C., Burlet N., Ethgen D., Montague T., Dabrowski C., Reginster J.Y., Osteoarthritis, magnetic resonance imaging, and biochemical markers: A one year prospective study, Ann Rheum Dis, 65, 8, pp. 1050-1054, (2006)

[7]

Conrozier T., Ferrand F., Poole A.R., Verret C., Mathieu P., Ionescu M., Vincent F., Piperno M., Spiegel A., Vignon E., Differences in biomarkers of type II collagen in atrophic and hypertrophic osteoarthritis of the hip: Implications for the differing pathobiologies, Osteoarthritis Cartilage, 15, 4, pp. 462-467, (2007)

[8]

Sharif M., Kirwan J., Charni N., Sandell L.J., Whittles C., Garnero P., A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis-association with disease progression, Rheumatology, 46, 6, pp. 938-943, (2007)

[9]

Garnero P., Charni N., Juillet F., Conrozier T., Vignon E., Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis, Ann Rheum Dis, 65, pp. 1639-1644, (2006)

[10]

Mazieres B., Garnero P., Gueguen A., Abbal M., Berdah L., Lesquesne M., Nguyen M., Salles J.-P., Vignon E., Dougados M., Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort, Ann Rheum Dis, 65, pp. 354-359, (2006)

← 1 2 3 →